Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma

M. P. Leonard, R. D. Jeffs, John Phillip Gearhart, D. S. Coffey

Research output: Contribution to journalArticle

Abstract

An analysis of the potential of recombinant human tumor necrosis factor to enhance the radiosensitivity of C1300 murine neuroblastoma was undertaken. Female A/J mice bearing C1300 murine neuroblastoma (right hindlimb) underwent the following treatments: group 1-0.25 cc normal saline intraperitoneally times 2, group 2-0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2, group 3-400 cGy. right hindlimb, group 4-800 cGy. right hindlimb, group 5-400 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2 and group 6-800 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2. All animals were followed for 21 days after treatment initiation with interval measurements of tumor volume. All single modality treatments were more effective than normal saline in reducing average tumor volumes during the study period (800 cGy. equals recombinant human tumor necrosis factor greater than 400 cGy. greater than normal saline). The addition of recombinant human tumor necrosis factor to radiotherapy moderately augmented antitumor response at radiation doses of 400 cGy. but marked enhancement was attained at radiation doses of 800 cGy. (p

Original languageEnglish (US)
Pages (from-to)743-746
Number of pages4
JournalJournal of Urology
Volume148
Issue number2 II
StatePublished - 1992
Externally publishedYes

Fingerprint

Radiation Tolerance
Neuroblastoma
Hindlimb
Tumor Burden
Radiation
human TNF protein
Radiotherapy
Therapeutics

Keywords

  • animals, laboratory
  • neuroblastoma
  • tumor necrosis factor

ASJC Scopus subject areas

  • Urology

Cite this

Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma. / Leonard, M. P.; Jeffs, R. D.; Gearhart, John Phillip; Coffey, D. S.

In: Journal of Urology, Vol. 148, No. 2 II, 1992, p. 743-746.

Research output: Contribution to journalArticle

@article{4baa08447a1344328c2d65b853813295,
title = "Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma",
abstract = "An analysis of the potential of recombinant human tumor necrosis factor to enhance the radiosensitivity of C1300 murine neuroblastoma was undertaken. Female A/J mice bearing C1300 murine neuroblastoma (right hindlimb) underwent the following treatments: group 1-0.25 cc normal saline intraperitoneally times 2, group 2-0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2, group 3-400 cGy. right hindlimb, group 4-800 cGy. right hindlimb, group 5-400 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2 and group 6-800 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2. All animals were followed for 21 days after treatment initiation with interval measurements of tumor volume. All single modality treatments were more effective than normal saline in reducing average tumor volumes during the study period (800 cGy. equals recombinant human tumor necrosis factor greater than 400 cGy. greater than normal saline). The addition of recombinant human tumor necrosis factor to radiotherapy moderately augmented antitumor response at radiation doses of 400 cGy. but marked enhancement was attained at radiation doses of 800 cGy. (p",
keywords = "animals, laboratory, neuroblastoma, tumor necrosis factor",
author = "Leonard, {M. P.} and Jeffs, {R. D.} and Gearhart, {John Phillip} and Coffey, {D. S.}",
year = "1992",
language = "English (US)",
volume = "148",
pages = "743--746",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2 II",

}

TY - JOUR

T1 - Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma

AU - Leonard, M. P.

AU - Jeffs, R. D.

AU - Gearhart, John Phillip

AU - Coffey, D. S.

PY - 1992

Y1 - 1992

N2 - An analysis of the potential of recombinant human tumor necrosis factor to enhance the radiosensitivity of C1300 murine neuroblastoma was undertaken. Female A/J mice bearing C1300 murine neuroblastoma (right hindlimb) underwent the following treatments: group 1-0.25 cc normal saline intraperitoneally times 2, group 2-0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2, group 3-400 cGy. right hindlimb, group 4-800 cGy. right hindlimb, group 5-400 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2 and group 6-800 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2. All animals were followed for 21 days after treatment initiation with interval measurements of tumor volume. All single modality treatments were more effective than normal saline in reducing average tumor volumes during the study period (800 cGy. equals recombinant human tumor necrosis factor greater than 400 cGy. greater than normal saline). The addition of recombinant human tumor necrosis factor to radiotherapy moderately augmented antitumor response at radiation doses of 400 cGy. but marked enhancement was attained at radiation doses of 800 cGy. (p

AB - An analysis of the potential of recombinant human tumor necrosis factor to enhance the radiosensitivity of C1300 murine neuroblastoma was undertaken. Female A/J mice bearing C1300 murine neuroblastoma (right hindlimb) underwent the following treatments: group 1-0.25 cc normal saline intraperitoneally times 2, group 2-0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2, group 3-400 cGy. right hindlimb, group 4-800 cGy. right hindlimb, group 5-400 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2 and group 6-800 cGy. right hindlimb plus 0.5 mcg./gm. recombinant human tumor necrosis factor intraperitoneally times 2. All animals were followed for 21 days after treatment initiation with interval measurements of tumor volume. All single modality treatments were more effective than normal saline in reducing average tumor volumes during the study period (800 cGy. equals recombinant human tumor necrosis factor greater than 400 cGy. greater than normal saline). The addition of recombinant human tumor necrosis factor to radiotherapy moderately augmented antitumor response at radiation doses of 400 cGy. but marked enhancement was attained at radiation doses of 800 cGy. (p

KW - animals, laboratory

KW - neuroblastoma

KW - tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0026639876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026639876&partnerID=8YFLogxK

M3 - Article

VL - 148

SP - 743

EP - 746

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2 II

ER -